Charles River Laboratories is partnering with Medigen Vaccine Biologics to help develop a next-generation enterovirus vaccine aimed at protecting against a broader range of these common and sometimes dangerous viruses.

What enteroviruses do

Enteroviruses are a large family causing illnesses ranging from mild hand-foot-and-mouth disease to severe neurological complications, particularly in young children.

Most infections are unremarkable — a rash, mouth sores, a few uncomfortable days. The concern is the minority that progress. Enterovirus 71 in particular can cause brainstem encephalitis, cardiopulmonary failure and death, and outbreaks in the Asia-Pacific region have produced substantial paediatric mortality.

The unpredictability is what makes them frightening. A common childhood illness that occasionally kills, with no reliable way to identify in advance which child will deteriorate, generates enormous anxiety during outbreak periods and heavy pressure on paediatric services.

The family also includes polioviruses, and non-polio enteroviruses have been associated with acute flaccid myelitis — a polio-like paralysis affecting children.

Where Medigen starts from

Medigen already markets Envacgen, an EV71 vaccine approved in Taiwan and Vietnam, and is developing a shot designed to cover broader enterovirus strains.

Having an approved product is a meaningful starting position. It means the company has demonstrated it can manufacture an enterovirus vaccine to regulatory standard, run the necessary trials and navigate approval — capabilities that do not transfer automatically but do not have to be built from nothing.

Why broadening coverage is the hard part

Protecting against one enterovirus and protecting against many are quite different problems.

Immunity to enteroviruses is largely type-specific — antibodies against EV71 neutralise EV71 and generally do little against coxsackieviruses or other members of the family. There is no shared surface feature that a single antibody response covers.

A broader vaccine therefore requires either combining multiple components, which multiplies manufacturing complexity and cost, or identifying conserved regions capable of eliciting cross-protective responses — a strategy pursued across many viral families and rarely successful.

Getting several components to work together adds its own difficulty: components can interfere with one another, producing weaker responses to some than each would generate alone.

What Charles River supplies

Charles River provides the technical backbone: characterisation and validation of the virus seed bank, chemistry, manufacturing and controls (CMC) work, analytical platforms including next-generation sequencing, biologics and virology testing, non-clinical development, and regulatory science.

The seed bank work is more consequential than it sounds. A viral vaccine is manufactured from a characterised stock of virus, and everything produced afterwards derives from it. Regulators require exhaustive documentation of what that stock contains, that it is genetically stable, and that it is free of adventitious agents — contaminating viruses that could otherwise be propagated into every batch.

Next-generation sequencing has changed this. It can detect contaminants at sensitivity conventional methods miss, and it is increasingly expected rather than optional — a capability requiring specialised platforms and expertise most vaccine developers do not maintain in-house.

Why this arrangement is standard

The collaboration targets IND-enabling studies and data for global investigational new drug applications and future clinical trials.

“We are excited to collaborate with MVC and apply our testing and NGS expertise for vaccine development,” said Charles River’s Kerstin Dolph.

The division of labour reflects how vaccine development now works. A developer holds the scientific concept and the candidate; a contract research organisation supplies the extensive, specialised, unglamorous work required to satisfy regulators.

Building that capability internally makes little sense for a company running one or two programmes, since it is used intensively at particular stages and idle between them. Renting it is both cheaper and, because a specialist does this continuously across many clients, frequently better executed.

Why the need is real

Broad enterovirus protection is an unmet need, especially in Asia-Pacific regions with recurrent outbreaks, where seasonal epidemics strain health systems and cause preventable child deaths.

Vaccines for diseases of the wrong markets

The geography of this programme explains something about why enterovirus vaccines have been slow to arrive.

Severe enterovirus 71 disease concentrates in the Asia-Pacific region, and hand-foot-and-mouth outbreaks there have repeatedly caused child deaths. In North America and Europe, enterovirus infections are common and severe complications are comparatively rare, so the disease has attracted limited attention from the companies with the largest vaccine development budgets.

The result is a pattern familiar across infectious disease: the vaccine gets developed by regional companies serving the affected markets, on smaller budgets, with approvals in the countries facing the burden rather than in the ones where regulatory approval carries global weight.

Envacgen’s approvals in Taiwan and Vietnam fit that shape exactly. Partnering with a large international contract research organisation is one way such programmes acquire the documentation standards that global filings demand — which is what makes an otherwise routine services agreement worth noting.

Deals pairing a vaccine developer with a large contract research organisation are how many programmes acquire the manufacturing and regulatory rigour needed to reach the clinic — particularly for candidates whose primary market is not the wealthy countries where most vaccine development capital sits. Business news.